Skip to main content

Tweets

The 2025 Rheumatology Year in Review The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders, ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines, and practices that https://t.co/71stL3X8my
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
ANAs and Autoantibodies https://t.co/AANvCKeAl0 https://t.co/SSPUxMEuLh
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
Are JAK Inhibitors Better at Pain Relief in RA? Among rheumatoid arthritis (RA) patients who responded to upadacitinib (Rinvoq) or adalimumab, those receiving upadacitinib had significantly less residual pain with treatment, according to a post hoc analysis of phase III trial https://t.co/QrbwlxIm3d
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
Review of Restless Legs Syndrome JAMA has published a full review of RLS - restless leg syndrome - a frequent, but often unrecognized, cause of poor sleep and the resultant hazards of insomnia. https://t.co/lPSMH3v7xS https://t.co/lbSfeNrfLz
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
Acupuncture in SpA metanalysis of 35 RCTs (2,591 AS pts) showed statistically significant improvements BASDAI score, BASFI score, ASDAS, VAS score, CRP level, and ESR level. Findings imited by high heterogeneity & the lack of large-scale, high-quality RCTs. https://t.co/gznAiNo0k4
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
Retrospective real-world study of 87 Behcets dz pts & inital Rx w/ IFX (n 45) or ADA (n 42) (2020 to 2025) & >60% were on AZA. Complete remission achieved in 76% (IFX) vs 79% (ADA) initially, & 89% vs 77% last visit. Same Rx retention but more relapses w/ IFX (38% v 17%) https://t.co/6FiuYe0GI9
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
UCAN CAN-DU study of 181 JIA pts starting biologics. Early Rx w/in 6 mos (n=35) assoc. w/ greater odds of achieving inactive arthritis (83% vs 57% in late starters (>12 mos). For each month of delay increased the odds of future active arthritis (after 6 mos) by 9%.

Dr. John Cush @RheumNow ( View Tweet )

1 month 1 week ago
Did you know theres a Subcutaneous (SC) rituximab (Hycela)? Its same RTX but combined w/ hyaluronidase, faster 5-7 minute injection Vs hours for IV RTX. FDA approved 2017 for Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL). Give 1st dose IV, then use SC RTX. https://t.co/piQ2ZhAOyf
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
French Retrospective study (2011-22) of 36129 adult psoriasis pts on biologics who recv antibiotics (9366/26% @ baseline, 61% during FU). Abx treatment assoc w/ 12% greater risk biologic D/C (HR 1.12); more for multiple Abx courses (HR 1.29; 95% CI, 1.24-1.35) https://t.co/2Jv5xCibyd
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
Congratulations to Lupus Research Alliance 2025 Global Science Award Recipients 1) Drs. Deepak Rao & Alexandra-Chloe Villani at Harvard affiliates; & 2) Dr. Caroline Jefferies at Cedars-Sinai. Grants will support interdisciplinary, collaborative, & synergistic projects in SLE https://t.co/GcfuEty75b
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
Rheums! Have a Rheumatology question or case for Jack Cush? Record it here, and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/RyalkevgRp https://t.co/DKfa52Cra7
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
Preoperative Semaglutide for 3 mos. prior to Total Knee Arthroplasty assoc w/ signif less Postoperative Adverse Events in NIDDM. Retrospective study of up to 745 T2DM needed TKR . 2-3 mos of GLP-1a reduces serious AEs by 75% (OR 0.25, P < 0.001). https://t.co/re57y9OvTN https://t.co/KNirmfdr2F
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
×